Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > While other biotech steam forward. DUG looks behind the

<< Previous

Bullboard Posts

Next >>

Comment by wagyusteakon Nov 27, 2020 2:18pm

73 Views

Post# 31990656

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:While other biotech steam forward. DUG looks behind the

porksniffer wrote:

MrMugsy wrote: Yes - I am betting it happens again ... on a bigger scale ... and I DO NOT believe we will get as lucky the next time.

The value will come from a much bigger global network and a much better connection to smaller drug companies.

Eventually, a pharma will want to bolt-on this network we are building. It will be a company that sees the advantage of adding ROW. Not even worth discussing as it is way in the future.

P.S. The share price means nothing to the development of ROW. We have cash so we don't have to worry about what others will pay for our shares in a financing ... unless ... there's something really big in our future. Don't count it out ... but then again, don't count on it either.

The share price is everything. This is the benchmark, this is what the market thinks of the company and it's direction....in real time.

Don't be so arrogant. Even JRG admitted it was pure luck. I still remember his quote .."better lucky then smart". To say it will happen on a bigger scale is nothing more than a pump job and wishful thinking. The CEO said himself it was a once in a lifetime chance. All based on a roll-up strategy and a tax inversion loophole. Those options are gone. This turd will be lucky to get back to old highs. The luck has run out, stop comparing to Palladin. The strategy will not work this time around.